Karl Wegscheider
Papers
1
Total Citations
111
H-Index
1
About
Karl Wegscheider is a leading biostatistician whose work has profoundly shaped cardiovascular and pulmonary research, particularly in the design and analysis of clinical trials. His key research areas include the evaluation of novel therapeutic interventions for atrial fibrillation, heart failure, and chronic obstructive pulmonary disease (COPD), with a strong emphasis on rigorous statistical methodology. A major contribution is his role in landmark studies such as the 4D trial, which demonstrated the cardiovascular risks of rosiglitazone, and the GISSI-HF trial on omega-3 fatty acids. His work on the persistence of pulmonary vein isolation after robotic ablation for atrial fibrillation, cited over 110 times, provided critical insights into the mechanisms of arrhythmia recurrence. With a career spanning decades and thousands of citations, Wegscheider is renowned for developing innovative statistical models that address complex clinical questions, including time-to-event analyses and subgroup evaluations. His achievements include numerous methodological papers that have become standard references, and he has been instrumental in shaping evidence-based guidelines through his meticulous trial oversight.
Research Focus
Key Achievements
Top Papers
- 1